Halozyme to Participate in Upcoming Investor Conferences
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
聖地亞哥，2024年5月8日 /PRNewswire/ — Halozyme Therapeutics, Inc.（納斯達克股票代碼：HALO）（“Halozyme”）今天宣佈，首席財務官妮可·拉布羅斯計劃在以下投資者會議上主持和主持投資者會議：
|
Event: |
The Citizens JMP Life Sciences Conference | |||
|
Format: |
Fireside Chat and 1x1 Meetings | |||
|
Presentation Date: |
Tuesday, May 14, 2024 | |||
|
Presentation Time: |
7:00 a.m. PT / 10:00 a.m. ET | |||
|
Location: |
New York, NY | |||
| Event: |
Benchmark 2024 Healthcare House Call Virtual Conference | |||
|
Format: |
1x1 Meetings | |||
|
Date: |
Tuesday, May 21 and Wednesday, May 22, 2024 |
|
活動： |
Citizens JMP 生命科學會議 | |||
|
格式： |
爐邊聊天和 1x1 會議 | |||
|
演示日期： |
2024 年 5 月 14 日，星期二 | |||
|
演講時間： |
太平洋時間上午 7:00 /美國東部時間上午 10:00 | |||
|
地點： |
紐約，紐約 | |||
| 活動： |
Benchmark 2024 醫療保健公司電話會議虛擬會議 | |||
|
格式： |
1x1 會議 | |||
|
日期： |
2024 年 5 月 21 日星期二和 5 月 22 日星期三 |
A live audio webcast of the JMP presentation will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
JMP演示文稿的網絡直播將在公司網站的投資者關係部分播出。網絡音頻廣播的重播將在會議結束後的90天內提供。
About Halozyme
關於 Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme是一家生物製藥公司，致力於提供顛覆性解決方案，以改善新興和成熟療法的患者體驗和療效。作爲 ENHANZE 的創新者 採用專有酶rHupH20的藥物遞送技術，Halozyme的商業驗證解決方案用於促進注射藥物和液體的皮下輸送，目標是減輕患者的治療負擔。Halozyme在全球100多個市場使用了七種商業化產品，在上市後使用了超過80萬名患者的生活，並已授權其ENHANZE 向領先的製藥和生物技術公司提供技術，包括羅氏、武田、輝瑞、詹森、艾伯維、禮來、百時美施貴寶、argenx、ViiV Healthcare、Chugai Pharmaceutical和Acumen Pharmicals。
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme還使用其先進的自動注射器技術爲自己或與合作伙伴開發、製造和商業化藥物器械組合產品，這些產品旨在提供商業或功能優勢，例如提高便利性、可靠性和耐受性，增強患者的舒適度和依從性。該公司有兩種商業專有產品，Hylenex 還有 XYOSTED，與包括梯瓦製藥和Idorsia Pharmicals在內的多家制藥公司合作了商業產品和正在進行的產品開發計劃。
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Halozyme總部位於加利福尼亞州聖地亞哥，在新澤西州尤因和明尼蘇達州明尼頓卡設有辦事處。明尼頓卡也是其運營設施的所在地。
For more information visit and connect with us on LinkedIn and Twitter.
欲了解更多信息，請訪問我們的領英和推特並聯系我們。
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
聯繫人：
Bui 有軌電車
投資者關係和企業傳播副總裁
609-359-3016
[電子郵件保護]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
薩曼莎·加斯帕
Teneo
212-886-9356
[電子郵件保護]
SOURCE Halozyme Therapeutics, Inc.
來源 Halozyme Therapeutics, Inc.